Avalo Therapeutics, Inc.AVTXNASDAQ
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank100
3Y CAGR+47.9%
5Y CAGR+21.9%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
+47.9%/yr
Annual compound
5Y CAGR
+21.9%/yr
Recent acceleration
Percentile
P100
Near historical high
vs 5Y Ago
2.7x
Strong expansion
Streak
1 yr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| 2024 | 277.81% |
| 2023 | -55.97% |
| 2022 | -47.68% |
| 2021 | 85.86% |
| 2020 | 173.65% |
| 2019 | 103.30% |
| 2018 | 32.34% |
| 2017 | -56.92% |
| 2016 | 54.09% |
| 2015 | -46.19% |